Zidovudine in AIDS dementia complex.
نویسندگان
چکیده
منابع مشابه
Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
OBJECTIVE To determine the incidence of HIV dementia and opportunistic brain disease in AIDS relative to the use of licensed antiretoviral medication (zidovudine, zalcitabine, didanosine, and stavudine). METHOD Medical records were evaluated retrospectively in a longitudinal cohort of 1109 patients with AIDS during the period 1991-4. Treatment groups were defined by start and duration of zido...
متن کاملPathogenic mechanisms of neuronal damage in the AIDS dementia complex.
It has become clear that infection with HIV1 is capable of causing a progressive syndrome of neurological disease that is not strictly dependent upon the state of immunosuppression in the infected individual.' Although the central nervous system (CNS) is often the target of opportunistic infections in the later stages of AIDS related complex (ARC) or in AIDS itself, the AIDS dementia complex (A...
متن کاملHAART & the molecular biology of AIDS dementia complex.
The era of highly active antiretroviral therapy (HAART) has led to a considerable decline in the HIV disease progression rates and HIV-1-related opportunistic infections especially in developed countries. Unfortunately, antiretroviral treatment for almost 90 per cent of the HIV-infected population is not available because of cost concerns. Although a number of studies have shown uniform impact ...
متن کاملThe blood transfusion service and zidovudine treatment for AIDS.
Points Adult epiglottitis (P D Whiteson and J Waldron); Impotence: treatment by auto-injection of vasoactive drugs (K M Desai and J C Gingell); Effects of maternal smoking on the newborn infant (R A Pastel); Leukaemia risks near nuclear sites (L Hawkins and D * All letters must be typed with double spacing and signed by all authors. * No letter should be more than 400 words. * For letters on sc...
متن کاملResistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
The relationships among treatment regimens, plasma human immunodeficiency virus (HIV) RNA levels, and resistance mutations to saquinavir (codons 48 and 90) and zidovudine (codon 215) were examined in a cohort of 144 patients from the AIDS Clinical Trials Group 229 study. After 24-40 weeks of therapy, no patients who had received the two-drug combination (zidovudine plus saquinavir) had only cod...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1989
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.299.6709.1218-a